GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
- Mechanism
- Curator reviewed
GlycoPEG-GCSF is a long-acting, GlycoPEGylated granulocyte colony stimulating factor for the treatment of neutropenia. G-CSF is prescribed to stimulate the production of neutrophils, and is approved for sale in major markets around the world for the treatment of neutropenia associated with myelosuppressive chemotherapy. Neutropenia is a severe reduction in the number of neutrophils (mature white blood cells) in the circulating blood, commonly associated with cancer chemotherapy. Patients with neutropenia are at increased risk of developing serious infection. If not treated promptly, neutropenia can be life-threatening.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of GlycoPEG-GCSF, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account